Mirae Asset Global Investments Co. Ltd. Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mirae Asset Global Investments Co. Ltd. lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 47.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,684 shares of the medical equipment provider's stock after buying an additional 3,772 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Lantheus were worth $1,041,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Signaturefd LLC raised its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 146 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Lantheus in the third quarter valued at $25,000. Finally, CWM LLC boosted its holdings in Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock valued at $82,000 after acquiring an additional 290 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have recently commented on LNTH shares. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial restated a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average price target of $131.86.

Lantheus Stock Down 2.5 %

Shares of Lantheus stock traded down $2.02 during trading hours on Friday, reaching $79.94. 737,336 shares of the stock traded hands, compared to its average volume of 709,331. The company has a 50 day moving average price of $91.43 and a 200 day moving average price of $97.71. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.